| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 63 | 2023 | 2325 | 4.240 |
Why?
|
| Contrast Media | 38 | 2023 | 435 | 3.910 |
Why?
|
| Peroxidase | 12 | 2023 | 70 | 3.590 |
Why?
|
| Fluorescent Dyes | 21 | 2019 | 204 | 2.840 |
Why?
|
| Oligodeoxyribonucleotides | 9 | 2019 | 242 | 2.130 |
Why?
|
| Polyethylene Glycols | 17 | 2019 | 172 | 1.840 |
Why?
|
| Molecular Imaging | 7 | 2017 | 52 | 1.800 |
Why?
|
| Organometallic Compounds | 8 | 2023 | 71 | 1.630 |
Why?
|
| Polylysine | 12 | 2019 | 49 | 1.490 |
Why?
|
| Nanoparticles | 4 | 2020 | 552 | 1.380 |
Why?
|
| NF-kappa B | 5 | 2019 | 436 | 1.340 |
Why?
|
| Carbocyanines | 12 | 2017 | 31 | 1.320 |
Why?
|
| ErbB Receptors | 5 | 2026 | 129 | 1.310 |
Why?
|
| Intracranial Aneurysm | 5 | 2024 | 384 | 1.300 |
Why?
|
| Endothelium, Vascular | 7 | 2020 | 180 | 1.270 |
Why?
|
| Gadolinium DTPA | 19 | 2018 | 84 | 1.240 |
Why?
|
| Animals | 102 | 2023 | 21494 | 1.170 |
Why?
|
| Biosensing Techniques | 3 | 2019 | 126 | 1.070 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 89 | 0.940 |
Why?
|
| Image Enhancement | 6 | 2014 | 196 | 0.910 |
Why?
|
| Drug Carriers | 8 | 2019 | 190 | 0.910 |
Why?
|
| Aneurysm | 2 | 2020 | 58 | 0.900 |
Why?
|
| Enzymes | 3 | 2013 | 35 | 0.890 |
Why?
|
| Ferric Compounds | 10 | 2015 | 42 | 0.860 |
Why?
|
| Glioma | 4 | 2013 | 101 | 0.850 |
Why?
|
| Rats | 37 | 2021 | 2005 | 0.850 |
Why?
|
| Pentetic Acid | 11 | 2012 | 33 | 0.830 |
Why?
|
| Luminescent Proteins | 7 | 2022 | 129 | 0.830 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 2020 | 279 | 0.790 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2019 | 204 | 0.790 |
Why?
|
| Mice | 55 | 2020 | 11183 | 0.780 |
Why?
|
| Oligonucleotides | 2 | 2020 | 229 | 0.770 |
Why?
|
| Fluorine | 2 | 2020 | 9 | 0.760 |
Why?
|
| Liposomes | 9 | 2014 | 117 | 0.760 |
Why?
|
| Gold | 2 | 2015 | 235 | 0.760 |
Why?
|
| Brain Neoplasms | 7 | 2013 | 323 | 0.730 |
Why?
|
| Fluorescence Resonance Energy Transfer | 6 | 2013 | 84 | 0.730 |
Why?
|
| Image Processing, Computer-Assisted | 9 | 2020 | 715 | 0.720 |
Why?
|
| Neoplasms | 7 | 2022 | 1378 | 0.710 |
Why?
|
| Optical Imaging | 2 | 2022 | 77 | 0.690 |
Why?
|
| Disease Models, Animal | 12 | 2020 | 2327 | 0.680 |
Why?
|
| Gadolinium | 7 | 2012 | 111 | 0.670 |
Why?
|
| Molecular Probes | 3 | 2017 | 34 | 0.670 |
Why?
|
| Genes, Reporter | 6 | 2009 | 257 | 0.660 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 63 | 0.650 |
Why?
|
| Anti-HIV Agents | 2 | 2019 | 139 | 0.650 |
Why?
|
| HIV Infections | 2 | 2019 | 961 | 0.650 |
Why?
|
| Vascular Remodeling | 1 | 2020 | 23 | 0.640 |
Why?
|
| NF-kappa B p50 Subunit | 3 | 2011 | 27 | 0.630 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2019 | 28 | 0.630 |
Why?
|
| Antibodies, Monoclonal | 7 | 2013 | 875 | 0.630 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 123 | 0.620 |
Why?
|
| Dextrans | 6 | 2015 | 46 | 0.620 |
Why?
|
| Cell Line, Tumor | 12 | 2017 | 1573 | 0.620 |
Why?
|
| DNA | 5 | 2011 | 853 | 0.610 |
Why?
|
| E-Selectin | 4 | 2006 | 19 | 0.610 |
Why?
|
| Rabbits | 10 | 2023 | 343 | 0.610 |
Why?
|
| Genetic Therapy | 9 | 2004 | 851 | 0.600 |
Why?
|
| Neovascularization, Pathologic | 11 | 2005 | 140 | 0.590 |
Why?
|
| Polymers | 6 | 2013 | 332 | 0.580 |
Why?
|
| Nucleic Acid Conformation | 3 | 2013 | 241 | 0.580 |
Why?
|
| Fluorescence | 5 | 2013 | 93 | 0.570 |
Why?
|
| Iron | 9 | 2023 | 156 | 0.570 |
Why?
|
| Humans | 73 | 2026 | 65872 | 0.560 |
Why?
|
| Cytoplasm | 2 | 2019 | 283 | 0.560 |
Why?
|
| Monophenol Monooxygenase | 3 | 2007 | 8 | 0.560 |
Why?
|
| Tumor Cells, Cultured | 15 | 2002 | 426 | 0.560 |
Why?
|
| Endothelial Cells | 3 | 2009 | 216 | 0.560 |
Why?
|
| Early Diagnosis | 1 | 2019 | 95 | 0.550 |
Why?
|
| Peptide Hydrolases | 1 | 2019 | 79 | 0.550 |
Why?
|
| Precision Medicine | 1 | 2020 | 134 | 0.550 |
Why?
|
| Transfection | 12 | 2006 | 700 | 0.540 |
Why?
|
| Neoplasm Transplantation | 17 | 2013 | 167 | 0.540 |
Why?
|
| Islets of Langerhans | 1 | 2019 | 286 | 0.540 |
Why?
|
| Chelating Agents | 4 | 2012 | 49 | 0.530 |
Why?
|
| Technetium | 5 | 2003 | 68 | 0.520 |
Why?
|
| Intracellular Space | 1 | 2017 | 33 | 0.520 |
Why?
|
| Metal Nanoparticles | 3 | 2015 | 191 | 0.500 |
Why?
|
| Carrier Proteins | 4 | 2012 | 719 | 0.500 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 70 | 0.500 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2014 | 202 | 0.500 |
Why?
|
| Adenocarcinoma | 8 | 2005 | 367 | 0.490 |
Why?
|
| Fluorocarbons | 1 | 2017 | 56 | 0.490 |
Why?
|
| Adoptive Transfer | 2 | 2007 | 145 | 0.480 |
Why?
|
| Tissue Distribution | 13 | 2019 | 292 | 0.480 |
Why?
|
| Diagnostic Imaging | 7 | 2013 | 274 | 0.480 |
Why?
|
| HIV-1 | 2 | 2019 | 710 | 0.480 |
Why?
|
| Microscopy, Fluorescence | 12 | 2019 | 401 | 0.480 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2026 | 198 | 0.470 |
Why?
|
| Gliosarcoma | 6 | 2003 | 7 | 0.470 |
Why?
|
| Photoacoustic Techniques | 1 | 2015 | 4 | 0.470 |
Why?
|
| Mice, Nude | 16 | 2012 | 287 | 0.470 |
Why?
|
| Cell Nucleus | 1 | 2019 | 634 | 0.470 |
Why?
|
| Radionuclide Imaging | 13 | 2005 | 129 | 0.460 |
Why?
|
| Phantoms, Imaging | 8 | 2018 | 242 | 0.460 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2012 | 203 | 0.460 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2015 | 8 | 0.460 |
Why?
|
| Lung Neoplasms | 3 | 2026 | 712 | 0.450 |
Why?
|
| Immunoglobulin Fab Fragments | 4 | 2021 | 33 | 0.450 |
Why?
|
| Models, Molecular | 4 | 2013 | 1161 | 0.440 |
Why?
|
| Cell Line | 8 | 2020 | 2032 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 631 | 0.420 |
Why?
|
| Oxides | 8 | 2000 | 36 | 0.410 |
Why?
|
| Base Pairing | 2 | 2013 | 42 | 0.410 |
Why?
|
| Genetic Vectors | 7 | 2003 | 930 | 0.410 |
Why?
|
| Annexin A5 | 6 | 2005 | 20 | 0.410 |
Why?
|
| Heterocyclic Compounds | 3 | 2006 | 12 | 0.410 |
Why?
|
| Biomimetics | 1 | 2014 | 33 | 0.400 |
Why?
|
| Gene Transfer Techniques | 5 | 2004 | 325 | 0.400 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 80 | 0.400 |
Why?
|
| Cell Membrane | 6 | 2003 | 506 | 0.390 |
Why?
|
| Macromolecular Substances | 2 | 2013 | 162 | 0.390 |
Why?
|
| Brain Ischemia | 3 | 2014 | 424 | 0.390 |
Why?
|
| Aneurysm, Ruptured | 1 | 2014 | 82 | 0.380 |
Why?
|
| Peroxidases | 2 | 2019 | 6 | 0.380 |
Why?
|
| Neuroimaging | 1 | 2014 | 170 | 0.370 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 222 | 0.370 |
Why?
|
| Electron Spin Resonance Spectroscopy | 3 | 2008 | 24 | 0.370 |
Why?
|
| Molecular Structure | 8 | 2011 | 315 | 0.370 |
Why?
|
| Coordination Complexes | 1 | 2012 | 9 | 0.370 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2013 | 44 | 0.360 |
Why?
|
| Antineoplastic Agents | 4 | 2005 | 645 | 0.360 |
Why?
|
| Female | 34 | 2026 | 34459 | 0.360 |
Why?
|
| Neoplasms, Experimental | 4 | 2003 | 77 | 0.350 |
Why?
|
| Horseradish Peroxidase | 2 | 2011 | 14 | 0.340 |
Why?
|
| Neovascularization, Physiologic | 2 | 2009 | 113 | 0.340 |
Why?
|
| Genetic Engineering | 2 | 2003 | 114 | 0.330 |
Why?
|
| Mutation | 5 | 2026 | 2674 | 0.330 |
Why?
|
| Prostatic Neoplasms | 3 | 2006 | 505 | 0.330 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 51 | 0.330 |
Why?
|
| Interleukin-1 | 3 | 2006 | 154 | 0.310 |
Why?
|
| Inflammation | 4 | 2023 | 1196 | 0.310 |
Why?
|
| Carcinoma, Lewis Lung | 3 | 2005 | 5 | 0.300 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 30 | 0.300 |
Why?
|
| Serotonin | 2 | 2019 | 62 | 0.290 |
Why?
|
| Carotid Artery Diseases | 1 | 2009 | 61 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2005 | 22 | 0.290 |
Why?
|
| Indazoles | 2 | 2005 | 19 | 0.280 |
Why?
|
| Green Fluorescent Proteins | 8 | 2012 | 372 | 0.280 |
Why?
|
| Indium Radioisotopes | 7 | 2007 | 41 | 0.280 |
Why?
|
| Gene Expression | 3 | 2002 | 858 | 0.280 |
Why?
|
| Brain | 3 | 2015 | 1672 | 0.280 |
Why?
|
| Binding Sites | 7 | 2012 | 923 | 0.280 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2007 | 16 | 0.270 |
Why?
|
| Oxidation-Reduction | 2 | 2023 | 328 | 0.270 |
Why?
|
| Water | 5 | 2022 | 323 | 0.270 |
Why?
|
| Proteins | 4 | 2008 | 764 | 0.260 |
Why?
|
| Plasmids | 3 | 2006 | 294 | 0.260 |
Why?
|
| Drug Combinations | 3 | 2019 | 167 | 0.260 |
Why?
|
| Male | 28 | 2026 | 31435 | 0.260 |
Why?
|
| Amino Acids | 3 | 2013 | 149 | 0.260 |
Why?
|
| Glucose Oxidase | 1 | 2007 | 5 | 0.260 |
Why?
|
| Positron-Emission Tomography | 2 | 2021 | 233 | 0.260 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2019 | 136 | 0.260 |
Why?
|
| Cells, Cultured | 9 | 2014 | 2192 | 0.260 |
Why?
|
| Mammary Neoplasms, Experimental | 6 | 2003 | 55 | 0.250 |
Why?
|
| Blood Volume | 7 | 2012 | 40 | 0.240 |
Why?
|
| Melanins | 3 | 2007 | 24 | 0.240 |
Why?
|
| Polyethyleneimine | 1 | 2006 | 10 | 0.230 |
Why?
|
| Blood Vessels | 3 | 2015 | 63 | 0.230 |
Why?
|
| Neoplasm, Residual | 1 | 2026 | 53 | 0.230 |
Why?
|
| Gallium Radioisotopes | 1 | 2005 | 15 | 0.230 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2020 | 141 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2005 | 83 | 0.230 |
Why?
|
| Technetium Tc 99m Pentetate | 6 | 1998 | 11 | 0.220 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 32 | 0.220 |
Why?
|
| Peptides | 2 | 1999 | 593 | 0.210 |
Why?
|
| Mice, Inbred DBA | 3 | 2014 | 84 | 0.210 |
Why?
|
| Umbilical Veins | 3 | 2009 | 14 | 0.210 |
Why?
|
| Apoptosis | 4 | 2005 | 1099 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2026 | 186 | 0.200 |
Why?
|
| Drug Stability | 3 | 2014 | 145 | 0.200 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 220 | 0.200 |
Why?
|
| Muscle, Skeletal | 4 | 2022 | 788 | 0.200 |
Why?
|
| Rats, Nude | 3 | 2013 | 25 | 0.190 |
Why?
|
| Radiopharmaceuticals | 3 | 2000 | 196 | 0.190 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 710 | 0.190 |
Why?
|
| Transplantation, Heterologous | 5 | 2011 | 241 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2000 | 503 | 0.190 |
Why?
|
| Glycerol | 1 | 2022 | 34 | 0.190 |
Why?
|
| Endopeptidases | 2 | 1999 | 68 | 0.180 |
Why?
|
| Permeability | 2 | 2020 | 52 | 0.180 |
Why?
|
| Oxygen | 3 | 2006 | 324 | 0.180 |
Why?
|
| Isotope Labeling | 3 | 2002 | 69 | 0.180 |
Why?
|
| Kinetics | 4 | 2012 | 760 | 0.180 |
Why?
|
| Viruses | 1 | 2002 | 82 | 0.170 |
Why?
|
| Immunoblotting | 3 | 2012 | 202 | 0.170 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2011 | 626 | 0.170 |
Why?
|
| Immunohistochemistry | 6 | 2018 | 901 | 0.170 |
Why?
|
| Reperfusion | 2 | 2018 | 38 | 0.170 |
Why?
|
| Cysteamine | 1 | 2000 | 3 | 0.170 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2012 | 465 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 2 | 1998 | 23 | 0.160 |
Why?
|
| Cerebral Angiography | 2 | 2015 | 303 | 0.160 |
Why?
|
| Blood-Brain Barrier | 3 | 2012 | 99 | 0.160 |
Why?
|
| Drug Delivery Systems | 3 | 2016 | 333 | 0.160 |
Why?
|
| Rats, Inbred F344 | 7 | 2000 | 58 | 0.160 |
Why?
|
| Stents | 1 | 2024 | 501 | 0.160 |
Why?
|
| Prodrugs | 1 | 2000 | 36 | 0.160 |
Why?
|
| Random Allocation | 1 | 2020 | 200 | 0.160 |
Why?
|
| Gene Expression Profiling | 1 | 2003 | 799 | 0.150 |
Why?
|
| Thrombospondin 1 | 1 | 1999 | 7 | 0.150 |
Why?
|
| Biomarkers, Tumor | 3 | 2003 | 527 | 0.150 |
Why?
|
| Ligands | 2 | 2014 | 414 | 0.150 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2014 | 206 | 0.150 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 3 | 0.150 |
Why?
|
| Benzoxazines | 1 | 2019 | 11 | 0.150 |
Why?
|
| Drug Liberation | 1 | 2019 | 23 | 0.150 |
Why?
|
| COS Cells | 3 | 2006 | 180 | 0.150 |
Why?
|
| Infrared Rays | 1 | 1999 | 19 | 0.150 |
Why?
|
| Cathepsins | 3 | 2012 | 34 | 0.140 |
Why?
|
| Alkynes | 1 | 2019 | 28 | 0.140 |
Why?
|
| Quinolones | 1 | 2019 | 25 | 0.140 |
Why?
|
| Cyclopropanes | 1 | 2019 | 57 | 0.140 |
Why?
|
| Gated Blood-Pool Imaging | 2 | 1998 | 11 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2014 | 1030 | 0.140 |
Why?
|
| Immunotoxins | 1 | 1998 | 7 | 0.140 |
Why?
|
| Skin | 2 | 2020 | 436 | 0.140 |
Why?
|
| Protein Binding | 6 | 2008 | 1638 | 0.130 |
Why?
|
| Cross-Linking Reagents | 4 | 2006 | 119 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2003 | 542 | 0.130 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2019 | 281 | 0.130 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2017 | 13 | 0.130 |
Why?
|
| Time Factors | 4 | 2014 | 3780 | 0.130 |
Why?
|
| Encephalitis | 1 | 2018 | 39 | 0.130 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2017 | 61 | 0.130 |
Why?
|
| Collagen | 3 | 2007 | 135 | 0.130 |
Why?
|
| Drug Resistance, Viral | 1 | 2019 | 167 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 6 | 2012 | 869 | 0.130 |
Why?
|
| Epidemiology | 1 | 2017 | 6 | 0.130 |
Why?
|
| Cysteine | 1 | 1997 | 108 | 0.130 |
Why?
|
| Pancreas | 3 | 2011 | 153 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 9 | 0.130 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2007 | 225 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2004 | 859 | 0.120 |
Why?
|
| Proteoglycans | 2 | 2007 | 34 | 0.120 |
Why?
|
| Biomarkers | 3 | 2014 | 1506 | 0.120 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2016 | 8 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2012 | 1045 | 0.120 |
Why?
|
| Laminin | 2 | 2007 | 81 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2000 | 930 | 0.120 |
Why?
|
| Pneumonia | 1 | 2019 | 295 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 169 | 0.120 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 1292 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2017 | 200 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2005 | 218 | 0.120 |
Why?
|
| Particle Size | 4 | 2004 | 432 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 1998 | 25 | 0.120 |
Why?
|
| Echoencephalography | 1 | 2015 | 14 | 0.110 |
Why?
|
| Feasibility Studies | 5 | 2009 | 592 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2002 | 708 | 0.110 |
Why?
|
| Excipients | 2 | 2012 | 50 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 6 | 2014 | 3507 | 0.110 |
Why?
|
| Cell Adhesion | 3 | 2006 | 218 | 0.110 |
Why?
|
| Cisplatin | 1 | 1996 | 145 | 0.110 |
Why?
|
| Base Sequence | 2 | 2013 | 1332 | 0.110 |
Why?
|
| Gentamicins | 1 | 1995 | 24 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 74 | 0.110 |
Why?
|
| Ferrosoferric Oxide | 8 | 2000 | 18 | 0.110 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2014 | 9 | 0.110 |
Why?
|
| Radio Waves | 1 | 2014 | 19 | 0.110 |
Why?
|
| Tomography, Optical | 2 | 2005 | 6 | 0.110 |
Why?
|
| Liver Regeneration | 1 | 2014 | 20 | 0.110 |
Why?
|
| Macrophages | 3 | 2009 | 1042 | 0.110 |
Why?
|
| Stroke | 2 | 2018 | 1226 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2014 | 26 | 0.110 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 67 | 0.100 |
Why?
|
| Manganese | 1 | 2014 | 20 | 0.100 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2014 | 40 | 0.100 |
Why?
|
| Motion | 1 | 2014 | 71 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1997 | 589 | 0.100 |
Why?
|
| Carcinoma, Ehrlich Tumor | 2 | 1991 | 3 | 0.100 |
Why?
|
| Reperfusion Injury | 1 | 2014 | 58 | 0.100 |
Why?
|
| Melanoma | 1 | 1997 | 336 | 0.100 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 139 | 0.100 |
Why?
|
| Endocytosis | 3 | 2005 | 152 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 1663 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2016 | 332 | 0.100 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 1993 | 5 | 0.100 |
Why?
|
| Cattle | 1 | 2014 | 320 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 375 | 0.100 |
Why?
|
| Thymidine | 2 | 2008 | 25 | 0.100 |
Why?
|
| Blood Proteins | 2 | 2012 | 84 | 0.100 |
Why?
|
| Cytoplasmic Granules | 1 | 1993 | 52 | 0.100 |
Why?
|
| Lipid Bilayers | 1 | 1993 | 53 | 0.100 |
Why?
|
| Aged | 3 | 2026 | 15155 | 0.100 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2012 | 17 | 0.090 |
Why?
|
| Membrane Fusion | 1 | 1993 | 67 | 0.090 |
Why?
|
| Mannitol | 1 | 2012 | 15 | 0.090 |
Why?
|
| 5-Hydroxytryptophan | 1 | 2012 | 3 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 559 | 0.090 |
Why?
|
| Cell Extracts | 1 | 2012 | 26 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 52 | 0.090 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 70 | 0.090 |
Why?
|
| Endothelial Growth Factors | 3 | 2003 | 22 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 1997 | 411 | 0.090 |
Why?
|
| Oligonucleotide Probes | 1 | 2012 | 41 | 0.090 |
Why?
|
| Adult | 4 | 2026 | 17595 | 0.090 |
Why?
|
| Lymphokines | 3 | 2003 | 67 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2014 | 312 | 0.090 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 81 | 0.090 |
Why?
|
| Antioxidants | 1 | 2014 | 252 | 0.090 |
Why?
|
| Insulin, Long-Acting | 1 | 2011 | 2 | 0.090 |
Why?
|
| Solubility | 1 | 2012 | 193 | 0.090 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2012 | 94 | 0.090 |
Why?
|
| Middle Aged | 3 | 2026 | 18518 | 0.090 |
Why?
|
| Wheat Germ Agglutinins | 3 | 1994 | 7 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2018 | 3340 | 0.090 |
Why?
|
| Cyclophosphamide | 4 | 2005 | 84 | 0.090 |
Why?
|
| Microcirculation | 3 | 2007 | 59 | 0.080 |
Why?
|
| Magnetics | 2 | 2006 | 54 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2003 | 432 | 0.080 |
Why?
|
| Indicators and Reagents | 3 | 2002 | 52 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 339 | 0.080 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 242 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 3 | 2006 | 95 | 0.080 |
Why?
|
| Body Water | 2 | 2008 | 16 | 0.080 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 101 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2009 | 8 | 0.080 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2009 | 14 | 0.080 |
Why?
|
| Nitrilotriacetic Acid | 1 | 2009 | 6 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 226 | 0.070 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2009 | 50 | 0.070 |
Why?
|
| Cell Transformation, Viral | 1 | 1989 | 15 | 0.070 |
Why?
|
| Concanavalin A | 1 | 1989 | 40 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2002 | 665 | 0.070 |
Why?
|
| Jurkat Cells | 3 | 2003 | 109 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 256 | 0.070 |
Why?
|
| Succinimides | 1 | 1988 | 17 | 0.070 |
Why?
|
| Cell Transplantation | 2 | 2006 | 41 | 0.070 |
Why?
|
| Spectrum Analysis | 2 | 2005 | 50 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2008 | 33 | 0.070 |
Why?
|
| Phenol | 1 | 2007 | 2 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2007 | 30 | 0.070 |
Why?
|
| Chromatography | 1 | 2007 | 15 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 4887 | 0.070 |
Why?
|
| Cell Death | 2 | 2007 | 289 | 0.070 |
Why?
|
| Hydrolysis | 1 | 2008 | 146 | 0.070 |
Why?
|
| Cations | 1 | 2008 | 64 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2009 | 162 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 1720 | 0.060 |
Why?
|
| Biochemistry | 1 | 1988 | 51 | 0.060 |
Why?
|
| Cell Movement | 1 | 2009 | 484 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2007 | 13 | 0.060 |
Why?
|
| Adolescent | 1 | 2018 | 6371 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2007 | 137 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 190 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2002 | 1584 | 0.060 |
Why?
|
| Catalysis | 1 | 2007 | 164 | 0.060 |
Why?
|
| Temperature | 1 | 2007 | 317 | 0.060 |
Why?
|
| Solutions | 1 | 2006 | 63 | 0.060 |
Why?
|
| Phosphatidylcholines | 2 | 1994 | 39 | 0.060 |
Why?
|
| Selectins | 1 | 2006 | 2 | 0.060 |
Why?
|
| Nuclease Protection Assays | 1 | 2006 | 3 | 0.060 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 83 | 0.060 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2006 | 85 | 0.060 |
Why?
|
| Erythrocyte Volume | 1 | 2005 | 1 | 0.060 |
Why?
|
| Deoxyribonuclease I | 1 | 2006 | 41 | 0.060 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 297 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2026 | 129 | 0.060 |
Why?
|
| Chymotrypsin | 2 | 1987 | 25 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2026 | 223 | 0.060 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 228 | 0.060 |
Why?
|
| Microscopy, Confocal | 2 | 2006 | 240 | 0.060 |
Why?
|
| Blood Volume Determination | 2 | 2003 | 3 | 0.060 |
Why?
|
| Surface Properties | 2 | 2024 | 283 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 922 | 0.060 |
Why?
|
| Dysprosium | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cathepsin B | 2 | 2002 | 14 | 0.050 |
Why?
|
| Arthritis, Experimental | 1 | 2005 | 30 | 0.050 |
Why?
|
| Receptors, Transferrin | 1 | 2005 | 33 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2018 | 5832 | 0.050 |
Why?
|
| Palmitic Acids | 1 | 1984 | 4 | 0.050 |
Why?
|
| Stearic Acids | 1 | 1984 | 9 | 0.050 |
Why?
|
| Molecular Weight | 2 | 2002 | 194 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2004 | 29 | 0.050 |
Why?
|
| Fibrosarcoma | 2 | 2003 | 14 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2005 | 346 | 0.050 |
Why?
|
| Enzymes, Immobilized | 1 | 1984 | 17 | 0.050 |
Why?
|
| Methotrexate | 1 | 2005 | 81 | 0.050 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2024 | 45 | 0.050 |
Why?
|
| Nanostructures | 1 | 2006 | 187 | 0.050 |
Why?
|
| Molecular Conformation | 2 | 2002 | 114 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 2 | 1998 | 52 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 233 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2005 | 962 | 0.050 |
Why?
|
| Refractometry | 1 | 2022 | 4 | 0.050 |
Why?
|
| Computer Simulation | 4 | 2012 | 488 | 0.050 |
Why?
|
| Luciferases | 1 | 2002 | 107 | 0.050 |
Why?
|
| Cell Division | 2 | 2000 | 451 | 0.050 |
Why?
|
| DNA, Complementary | 2 | 1999 | 165 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2002 | 58 | 0.050 |
Why?
|
| Photons | 1 | 2002 | 23 | 0.050 |
Why?
|
| Supine Position | 1 | 2002 | 35 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 228 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 144 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2002 | 88 | 0.040 |
Why?
|
| Suspensions | 2 | 2000 | 9 | 0.040 |
Why?
|
| Microscopy | 1 | 2002 | 99 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 1172 | 0.040 |
Why?
|
| Capillary Permeability | 2 | 1998 | 17 | 0.040 |
Why?
|
| Magnetite Nanoparticles | 2 | 2000 | 29 | 0.040 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2001 | 16 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2006 | 234 | 0.040 |
Why?
|
| Propanols | 1 | 2000 | 1 | 0.040 |
Why?
|
| Biotransformation | 1 | 2000 | 24 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2001 | 43 | 0.040 |
Why?
|
| Metallothionein | 1 | 2000 | 8 | 0.040 |
Why?
|
| Liver | 5 | 2014 | 879 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2007 | 911 | 0.040 |
Why?
|
| Phenols | 1 | 2000 | 77 | 0.040 |
Why?
|
| Neprilysin | 1 | 1999 | 9 | 0.040 |
Why?
|
| Cell Fractionation | 1 | 1999 | 32 | 0.040 |
Why?
|
| Protein Sorting Signals | 1 | 1999 | 55 | 0.040 |
Why?
|
| Mesoporphyrins | 1 | 1999 | 1 | 0.040 |
Why?
|
| Metalloporphyrins | 1 | 1999 | 3 | 0.040 |
Why?
|
| Hypotension | 1 | 1999 | 51 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2003 | 1635 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 1999 | 71 | 0.040 |
Why?
|
| Spin Labels | 1 | 1998 | 44 | 0.030 |
Why?
|
| Cell Survival | 2 | 2002 | 588 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1998 | 26 | 0.030 |
Why?
|
| Nitrobenzoates | 1 | 1998 | 5 | 0.030 |
Why?
|
| Sepharose | 1 | 1998 | 7 | 0.030 |
Why?
|
| Organotechnetium Compounds | 1 | 1998 | 28 | 0.030 |
Why?
|
| Biotinylation | 1 | 1998 | 36 | 0.030 |
Why?
|
| Kidney | 1 | 2000 | 460 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 1998 | 49 | 0.030 |
Why?
|
| Spermatic Cord | 1 | 1997 | 1 | 0.030 |
Why?
|
| Lysosomes | 1 | 1999 | 176 | 0.030 |
Why?
|
| Spermatic Cord Torsion | 1 | 1997 | 12 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 238 | 0.030 |
Why?
|
| Virion | 1 | 1998 | 122 | 0.030 |
Why?
|
| Biotin | 3 | 1996 | 54 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2019 | 541 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1998 | 387 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2003 | 22 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 1997 | 105 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2011 | 502 | 0.030 |
Why?
|
| Proton Pumps | 1 | 1996 | 6 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 2 | 1994 | 19 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 417 | 0.030 |
Why?
|
| Secretin | 1 | 1996 | 4 | 0.030 |
Why?
|
| Boston | 1 | 2017 | 259 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 516 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2026 | 5684 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1996 | 62 | 0.030 |
Why?
|
| Muscles | 2 | 1993 | 179 | 0.030 |
Why?
|
| Drug Implants | 1 | 1995 | 15 | 0.030 |
Why?
|
| Soft Tissue Infections | 1 | 1995 | 48 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 1995 | 90 | 0.030 |
Why?
|
| Imidocarb | 1 | 1994 | 1 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 1995 | 36 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2012 | 537 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 1590 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 1980 | 0.030 |
Why?
|
| Axonal Transport | 1 | 1994 | 32 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1995 | 88 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 1995 | 120 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2002 | 1235 | 0.030 |
Why?
|
| Colloids | 1 | 1994 | 51 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2005 | 47 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2014 | 63 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2026 | 6956 | 0.030 |
Why?
|
| Cell Cycle | 1 | 1996 | 398 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 1994 | 263 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 1994 | 96 | 0.020 |
Why?
|
| PC12 Cells | 1 | 1993 | 27 | 0.020 |
Why?
|
| Porosity | 1 | 1993 | 41 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 1993 | 173 | 0.020 |
Why?
|
| Asialoglycoproteins | 1 | 1993 | 1 | 0.020 |
Why?
|
| Escherichia coli | 1 | 1998 | 719 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 1993 | 14 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1994 | 237 | 0.020 |
Why?
|
| Pressure | 1 | 1993 | 80 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 1993 | 83 | 0.020 |
Why?
|
| Axons | 1 | 1993 | 124 | 0.020 |
Why?
|
| Phospholipids | 1 | 1993 | 81 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 1993 | 36 | 0.020 |
Why?
|
| Injections, Intravenous | 3 | 1998 | 160 | 0.020 |
Why?
|
| Micelles | 1 | 2012 | 84 | 0.020 |
Why?
|
| Molecular Probe Techniques | 1 | 2012 | 6 | 0.020 |
Why?
|
| Rhodamines | 3 | 2000 | 20 | 0.020 |
Why?
|
| Insulin Glargine | 1 | 2011 | 2 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2011 | 20 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 30 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2014 | 302 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 37 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1994 | 198 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1991 | 15 | 0.020 |
Why?
|
| Avidin | 1 | 1991 | 12 | 0.020 |
Why?
|
| Cytochalasin B | 1 | 1991 | 24 | 0.020 |
Why?
|
| Integrins | 1 | 1991 | 109 | 0.020 |
Why?
|
| Lipids | 1 | 1993 | 330 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 1991 | 141 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 491 | 0.020 |
Why?
|
| Trypsin | 1 | 1989 | 43 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 1989 | 97 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 80 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 75 | 0.020 |
Why?
|
| Carbodiimides | 1 | 1988 | 1 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 498 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1988 | 199 | 0.020 |
Why?
|
| Angiography | 1 | 2007 | 154 | 0.020 |
Why?
|
| Plant Lectins | 1 | 2006 | 7 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 665 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 42 | 0.020 |
Why?
|
| Response Elements | 1 | 2006 | 41 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 72 | 0.020 |
Why?
|
| P-Selectin | 1 | 2006 | 7 | 0.010 |
Why?
|
| Autoradiography | 2 | 1998 | 52 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 213 | 0.010 |
Why?
|
| Eye | 1 | 2006 | 60 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2006 | 518 | 0.010 |
Why?
|
| Leukocytes | 1 | 2006 | 110 | 0.010 |
Why?
|
| Annexins | 1 | 2005 | 8 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 2005 | 29 | 0.010 |
Why?
|
| Joints | 1 | 2005 | 33 | 0.010 |
Why?
|
| Palmitic Acid | 1 | 1984 | 14 | 0.010 |
Why?
|
| Cell Count | 1 | 2005 | 128 | 0.010 |
Why?
|
| Sucrose | 1 | 1984 | 30 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2005 | 65 | 0.010 |
Why?
|
| Sciatic Nerve | 2 | 1994 | 31 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1984 | 254 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 625 | 0.010 |
Why?
|
| Phosphatidylserines | 1 | 2003 | 15 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1193 | 0.010 |
Why?
|
| Hemangioendothelioma | 1 | 2003 | 5 | 0.010 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 23 | 0.010 |
Why?
|
| Camptothecin | 1 | 2002 | 29 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 158 | 0.010 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2001 | 8 | 0.010 |
Why?
|
| Metals, Rare Earth | 1 | 2001 | 7 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 611 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 2170 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2000 | 18 | 0.010 |
Why?
|
| Cytosine | 1 | 2000 | 31 | 0.010 |
Why?
|
| Bisbenzimidazole | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cathepsin H | 1 | 1999 | 1 | 0.010 |
Why?
|
| Herpesvirus 1, Human | 1 | 2000 | 83 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 1999 | 96 | 0.010 |
Why?
|
| Echo-Planar Imaging | 1 | 1998 | 36 | 0.010 |
Why?
|
| Half-Life | 1 | 1998 | 81 | 0.010 |
Why?
|
| DEAE-Dextran | 1 | 1998 | 1 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 79 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1998 | 14 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1998 | 19 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1999 | 254 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 129 | 0.010 |
Why?
|
| Corpus Callosum | 1 | 1998 | 42 | 0.010 |
Why?
|
| Neuroglia | 1 | 1998 | 81 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1998 | 140 | 0.010 |
Why?
|
| Spleen | 1 | 1998 | 476 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1998 | 274 | 0.010 |
Why?
|
| Homeostasis | 1 | 1999 | 383 | 0.010 |
Why?
|
| Streptavidin | 1 | 1996 | 32 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 60 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 96 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1996 | 21 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 193 | 0.010 |
Why?
|
| Thigh | 1 | 1995 | 28 | 0.010 |
Why?
|
| Models, Structural | 1 | 1995 | 25 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1998 | 334 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 117 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1994 | 15 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 1994 | 16 | 0.010 |
Why?
|
| Platelet Count | 1 | 1994 | 27 | 0.010 |
Why?
|
| Femoral Nerve | 1 | 1994 | 10 | 0.010 |
Why?
|
| Babesiosis | 1 | 1994 | 13 | 0.010 |
Why?
|
| Epitopes | 1 | 1996 | 291 | 0.010 |
Why?
|
| Horse Diseases | 1 | 1994 | 20 | 0.010 |
Why?
|
| Horses | 1 | 1994 | 53 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1994 | 185 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1996 | 672 | 0.010 |
Why?
|
| Sheep | 1 | 1994 | 194 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 1993 | 11 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1994 | 92 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1994 | 94 | 0.010 |
Why?
|
| Superior Colliculi | 1 | 1993 | 12 | 0.010 |
Why?
|
| Retinal Ganglion Cells | 1 | 1993 | 34 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1995 | 472 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1993 | 98 | 0.010 |
Why?
|
| Gels | 1 | 1993 | 78 | 0.010 |
Why?
|
| Cholesterol | 1 | 1994 | 264 | 0.010 |
Why?
|
| Fetuins | 1 | 1993 | 1 | 0.010 |
Why?
|
| Asialoglycoprotein Receptor | 1 | 1993 | 3 | 0.010 |
Why?
|
| Biological Transport | 1 | 1993 | 292 | 0.010 |
Why?
|
| Neurons | 1 | 1998 | 934 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 1992 | 7 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1993 | 179 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1996 | 741 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1988 | 111 | 0.000 |
Why?
|
| Imidoesters | 1 | 1987 | 1 | 0.000 |
Why?
|
| Dithionitrobenzoic Acid | 1 | 1987 | 4 | 0.000 |
Why?
|